Background: Osteoarthritis (OA) is a common joint disorder with increasing impact 32 in an aging society; however, there is no cure or effective treatments so far due to lack 33 of sufficient understanding of its pathogenesis. While genome-wide association studies 34 (GWAS) and DNA methylation profiling identified many non-coding loci associated 35 to OA, the interpretation of them remains challenging. 36
genes are enriched in pathways regulating ossification and mesenchymal stem cell 48 (MSC) differentiation. Consistently, the differentially accessible regions in OA are 49 7 separately, with parameters -true_rep -no_idr. Reads were mapped to the hg38 151 reference genome. Peaks were called by macs2 with default parameters in the pipeline. 152
Basic sequencing information and library quality metrics are listed in Additional file 1: 153 Table S2 . NucleoATAC was applied to infer genome-wide nucleosome positions and 154 occupancy from the ATAC-seq data [31] . Briefly, NucleoATAC were run for oLT and 155 iMT separately with default parameters, using bam files merging from all patients as 156 input, and the outputted nucleoatac_signal.bedgraph were used for aggregated plot 157 around TSS. 158
Previously annotated DNase I Hypersensitive Sites (DHS) were used to assess 159 the quality of our libraries. Briefly, a set of DHS defined in Roadmap Epigenomics 160
Project [32] were downloaded [33] and lifted over from hg19 to hg38 using UCSC 161 liftOver tool [34] (refer as Roadmap DHS thereafter). For each library, we calculated 162 the ratio of reads that fall within Roadmap DHS versus randomly chosen genomic 163 regions of the same total size (DHS enrichment score). It is noted that the DHS 164 enrichment score is in good correlation with enrichment qPCR for GAPDH (Additional 165 file 2: Figure S1b ). 166 167
Defining a set of unified accessible chromatin regions 168
Peaks from all 16 libraries were pooled and those that are within 300 bp were merged, 169 resulting in 615,454 merged raw peaks. Reads fall in raw peak regions were counted 170 for individual samples using bedtools v2.27.0 [35] . Read counts were normalized as 171 count-per-million (CPM) based on relative log expression normalization implemented 172 in edgeR v3.18.1 [36, 37] . In the end, we defined a set robust peaks (n=109,215) with ³ 173 2 CPM in at least 6 oLT or 6 iMT samples for all downstream analyses. 174 175 Peak annotation and differentially accessible peak identification 176 Peaks were annotated as promoters or enhancers based on their intersection with 177 promoter or enhancer as defined in Roadmap DHS [24] . Noted that a peak was 178 preferentially annotated as a promoter if it intersects both a promoter and an enhancer 179 DHS. Differentially accessible peaks between damaged (i.e. iMT) and intact (i.e. oLT) 180 tissues were identified using edgeR [36, 37] . Briefly, DHS enrichment score of each 181 sample were incorporated as continuous covariates in the design matrix of the 182 generalized linear model implemented in edgeR [36, 37] . The Benjamini-Hochberg 183 adjusted p-values (i.e. false discovery rate, FDR) was taken to measure the extent of 184 differential accessibility as used in Fig. 3b [39] , and a recent study [40] . SNPs 190 in linkage disequilibrium with these lead SNPs (i.e. proxy SNPs with r 2 > 0.5 and 191 distance limit of 500kb in any three population panels of the 1000 Genomes Project 192 pilot 1 data) were obtained from SNAP database [41] , resulting in 8,973 GWAS SNPs 193 associated with OA. As a negative control, GWAS SNPs associated with Parkinson's 194 disease were obtained the same way from NHGRI-EBI GWAS Catalog. Coordinates 195 for these SNPs in hg38 were obtained from dbSNP Build 150. 196
197

Definition of cell type-specific enhancers 198
Bed files for enhancer clusters with coordinated activity in 127 epigenomes, as well as 199 the density of clusters per cell type, were obtained from online database [33] (DNase I 200 9 regions selected with p < 1 × 10 -2 , lifted over from hg19 to hg38 using UCSC liftOver 201 tool). For each cell type, clusters with two-fold density than average (across all cell 202 types) were defined as specific and pooled. 203 204
Enrichment analysis for differentially accessible peaks 205
Fisher's exact test were applied to assess the enrichment for the following features in 206 the selected peaks: (1) GWAS SNPs associated with OA (n=8,973), (2) differentially 207 methylated loci (DML) associated with OA (n=9,265) [19, 42] , and (3) cell type-208 specific enhancers. Briefly, for the enrichment of (1) GWAS SNPs and (2) DML, peaks 209 were ranked by the extent of differential accessibility (as measured by FDR) and each 210 cumulative fraction of peaks was compared to all peaks. GWAS SNPs and DML [43] 211 associated with Parkinson's disease was used as a negative control. For enrichment of 212
(3) cell type-specific enhancers, differentially accessible peaks (FDR ≤ 0.05) were 213 compared to all peaks, and same number of randomly selected peaks were used as a 214 control. Permutation of peaks as control were done 25 times. 215
216
Linking enhancer peaks to their potential target genes 217 A promoter peak is assigned to a gene if it intersects with the transcription start sites 218 (TSS) of its transcript as defined in the FANTOM CAGE associated transcriptome [44] . 219
We noted that a promoter peak might be associated with multiple genes. An enhancer 220 peak is defined as linked to a target gene if it overlaps an expression quantitative trait 221 loci (eQTL) of the corresponding gene (GTEx V7, in any tissues with p < 1 × 10 -5 ) [45], 222 or is supported by putative enhancer-promoter linkage predicted by JEME method [46] [44] . Estimated read counts of a gene, defined as the sum of the estimated 231 read counts of its associated transcripts, were used as the input for differential gene 232 expression analysis using edgeR v3.18.1. In total, 3,293 genes were defined as 233 significantly differentially expressed between iMT and oLT (FDR ≤ 0.05). A gene is 234 defined as "consistently dysregulated both at the epigenomic and transcriptomic levels" 235 when it is upregulated (or downregulated) in RNA-seq with more (or less) accessible 236 promoters or enhancers in ATAC-seq (n= 371). 
Mapping chromatin accessibility of chondrocytes in OA knee cartilages 252
To investigate chromatin signatures in articular cartilage associated with OA, we 253 performed ATAC-seq on the chondrocytes isolated from the knee joints of patients. We 254 have previously shown that the oLT region (outer region of the lateral tibial plateau, 255
representing the intact cartilage) is a good control for comparing the iMT region (inner 256 region of medial tibial plateau, representing the damaged cartilage) as a model for OA 257 disease progression [16] , and the transcriptome and methylome of this model have been 258 characterized by us and the others [19, 20, 50, 51] . In this study, we performed ATAC-259 seq on the chondrocytes isolated from of the oLT and iMT regions of 8 patients 260 (Additional file 2: Figure S1a Table S2 ). In addition, the expected 265 nucleosome banding patterns were observed in the fragment size distribution for both 266 oLT and iMT libraries ( Fig. 1b ). When we applied nucleoATAC to infer genome-wide 267 nucleosome occupancy and positioning from ATAC-seq data [31], we found similar 268 aggregated signals around TSS for both oLT and iMT libraries, corresponding to -2, -269 1, +1, +2, +3 nucleosomes as well as nucleosome depletion region at upstream of TSS 270 ( Fig. 1c ). Thus, we concluded that our ATAC-seq libraries had good and 271 indistinguishable quality between oLT and iMT regions. Table  277 S3); 77,655 (71.1%) of which were annotated as enhancers and 18,410 (16.9%) as 278 promoters ( Fig. 2a ) based on Roadmap DHS annotations (Methods). To assess the 279 relevance of these peaks to OA, we intersected these peaks against Roadmap DHS, OA 280 GWAS SNPs and OA DML datasets. We found that both OA GWAS SNPs and OA 281 DML are significantly enriched in these peaks compared to all Roadmap DHS (GWAS 282 SNP: Odds ratio = 4.3, p < 2 × 10 -16 ; DML: Odds ratio = 1.8, p < 2 × 10 -16 , Fisher's 283 exact test), suggesting the peaks identified in this study are relevant to OA. In fact, 284 majority of the OA GWAS SNPs (75.49%) that overlap our ATAC-seq peaks fall 285 within annotated enhancers, which is consistent with the fact that GWAS SNPs reside 286 in enhancers [14, 52] . In this way, we identified 140 enhancers overlapping the OA 287 GWAS SNPs (Additional file 1: Table S4 ) and 727 enhancers overlapping the OA 288 DML (Additional file 1: Table S5 ). To further characterize these enhancers potentially 289 relevant to OA, we utilized public resources [25,26] to predict their target genes 290 (Methods). These enhancers and their predicted target genes represent candidates of 291 dysregulated transcriptional network during OA pathogenesis. This included the 292 previously identified OA associated genes, such as FGFR3 [53,54] (its enhancer 293 overlaps an OA GWAS SNP, Fig. 2b ) and PTEN [55] (its predicted enhancer overlaps 294 with an OA DML, Fig. 2c ), thus validating our approach. In addition, rs4775006 is a 295 proxy SNP of rs4646626 (r 2 = 0.816), which has previously been identified as a 296 suggestive OA risk locus (p = 9 × 10 -6 , [56]). We found this SNP hitting the accessible 297 enhancer region (chr15:57922910-57924140) in our samples, and predicted to target 298 the ALDH1A2 gene. Therefore, this study provides an accessible chromatin landscape 299 of cartilage tissue, which allows better interpretation of other genetic and epigenomic 300 data relevant to OA and other skeletomuscular disease related to cartilage tissue. 301 302
Identification of differentially accessible enhancers in OA 303
To compare the accessible chromatin landscape between the intact (oLT) and the 304 damaged (iMT) tissues, we performed principal component analysis on the peak signals 305 across the 16 samples. To identify the chromatin signatures relevant to OA, we performed differential 312 accessibility analysis between oLT and iMT using edgeR [37] . First and foremost, we 313 assessed the global relevance of the differential accessibility of peaks to OA. In Fig. 3b , 314 we investigated the relationship between the extent of differential accessibility of peaks 315 (measured by FDR) and their 1) compositions, 2) enrichment in OA GWAS SNPs, and 316
3) enrichment in OA DML. We found that the peaks that are more differentially 317 accessible (i.e. smaller FDR) contain substantially higher fraction of enhancers ( Fig.  318 3b, top panel), suggesting enhancers are more likely to be dysregulated than promoters 319 during OA disease progression. Moreover, peaks that are more differentially accessible 320 tend to be more enriched (i.e. higher odds ratio) in both OA GWAS SNPs and DML 321 (Methods, Fig. 3b , middle and lower panels). The differentially accessible enhancers 322 overlapping either OA GWAS SNP or OA DML are summarized in Table 1 and 2,  323 respectively. As a negative control, we also examined the GWAS SNPs and DML 324 associated with Parkinson's disease [43] , which is a neurodegenerative disease 325 pathologically unrelated to cartilage, and did not observe any substantial enrichment. 326
Taken together, these observations suggest the differential chromatin accessibility 327 measured in this study is relevant to OA disease progression in a specific manner. 328
We next determined the significantly differentially accessible peaks with FDR 329 Epigenomics Project [24] . We found these differential accessible enhancers are highly 346 enriched for enhancers that are specific to bone-related cell types in damaged tissues 347 (e.g. chondrocyte and osteoblast), as well as mesenchymal stem cells (Fig. 3e ). This 348 observation is consistent with the hypothesis that inappropriate activation of 349 endochondral ossification process might play a role in OA progression [59] , which is 350 thought to occur through differentiation of mesenchymal stem cells to chondrocytes or 351 osteoblasts, as well as hypertrophic differentiation of chondrocytes [60] . 352
In summary, we demonstrate that the differential accessible chromatin regions 353 identified in this study are enriched in OA-relevant enhancers supported by multiple 354 genetic and epigenome evidence. These differentially accessible enhancers and their 355 predicted target genes could be used for prioritization of candidate genes to be tested 356 for studying OA disease progression. 357
358
Motif enrichment analysis reveals transcription factors relevant to OA 359
In order to gain more insights into which regulatory pathways may be dysregulated in 360 OA, we next examined the enrichment of transcription factor binding motifs in the 361 differentially accessible regions. Enrichment analyses were performed separately for 362 the regions that are significantly more or less accessible in the damaged tissues, using 363 all accessible regions as background. Transcription factors with significantly enriched 364 motifs are summarized (Additional file 2: Figure S3b ), and their binding prediction in 365 robust peaks are listed (Additional file 1: Table S3 ). We note most of these transcription 366 factors belong to ETS and bZIP family; many of which are known to regulate genes 367 involved in bone or cartilage development, including To evaluate the effects of the dysregulated regulatory regions on gene expression in 379 OA, we reanalyzed the RNA-seq dataset from a different cohort that used the same 380 disease model (i.e. oLT vs. iMT) [15] and integrated it with the differentially accessible 381 regions identified in this study (Fig. 4a ). We first verified that the dysregulated 382 regulatory regions have detectable effects on the gene expression; the genes with more 383 accessible promoters or enhancers have significantly higher expression fold-changes 384 between oLT and iMT (p < 0.001, Student's t-test) than the ones with less accessible 385 promoters or enhancers (Fig. 4b) . To further investigate the congruence between these 386 transcriptomic and epigenomic changes, we overlapped the significant differentially 387 expressed genes (n=3,293, FDR £ 0.05) onto the genes with differentially accessible 388 promoters (n=255) or enhancers (n=2,406) ( Fig. 4c ). We find that their overlaps are 389 statistically significant (p < 0.001 in both promoters and enhancers, Fisher's exact test), 390 which further demonstrate the chromatin accessibility dataset from this study is 391 generally consistent with the transcriptomic dataset. As a result, we identified 371 genes 392 that are consistently dysregulated both at the epigenomic and transcriptomic levels, 393 representing a shortlist of OA-related genes candidates supported by multiple lines of 394 evidence (Fig. 4c , Additional file 1: Table S6 ). 395
To elucidate the biological pathways dysregulated in OA, we examined the 396 enrichment of gene ontology (GO) terms of the 371 OA-related candidate genes using 397 enrichR [48] (Figure 4d , top 30 terms listed). Overall, we observe the enrichment of 398 GO terms related to cell fate and differentiation, including MSC differentiation, 399 ossification and bone development ( Fig. 4d , dysregulated genes in each GO terms are 400 listed in Additional file 1: Table S7 ). In the 'positive regulation of ossification pathway', 401 two genes were identified to be more accessible and upregulated: SOX11 (only the 402 promoter is more accessible) and WNT5A (both the promoter and the enhancer are more 403 accessible) (Additional file 2: Figure S3b ). It has been shown that WNT5A protein can 404 induce matrix metalloproteinase production and cartilage destruction [67], and its 405 upregulation is consistent with ossification being an important process and signature of 406 Conventional epigenomic profiling at the chromatin level, such as chromatin 415 immunoprecipitation sequencing (ChIP-seq) and DNase-seq, is informative in 416 providing insights into the molecular mechanism underlying the regulation of gene 417 expression. However, applying these methods to clinically relevant tissue is less 418 feasible due to the requirement of large number of cells. Especially with the cartilage 419 tissues, the limited tissue sampling size and the extracellular matrix make collection of 420 sufficient cells difficult. One major advantage of ATAC-seq is that it can be achieved 421 with only thousands of cells, making the direct chromatin profiling of clinical samples 422 feasible. In this study, we applied ATAC-seq on OA samples to obtain a chromatin 423 accessibility map in articular cartilage, and identified regulatory regions associated with 424 18 OA. The lack of normal knee tissues due to difficulties associated with collecting them 425 is a limitation for studying OA. However, our previous studies of the pathology and 426 transcriptome showed that the oLT regions are very similar to normal [16, 20] . Thus, 427 the oLT regions could serve as a suitable alternative to normal control, which could 428 also reduce the inter-individual variations. 429
Our strategy of integrating the epigenomic data of clinically relevant tissues 430 with the publicly available genetic and transcriptomic data allowed us to better 431 understand how the identified loci may contribute to OA pathogenesis. Most of these 432 accessible chromatin regions are annotated enhancers and we linked them to their 433 putative target genes using public datasets. With this enhancer-gene map in 434 chondrocyte, we can now better interpret the previously identified OA GWAS SNPs or 435 OA differential methylated loci located lie outside of the coding regions. For example, 436
we have verified that the previously reported OA associated SNP rs4775006 is indeed 437 accessible in chondrocytes, that lies within the enhancer region of the predicted target 438 gene ALDH1A2. Since ALDH1A2 is inactivated in prechondrogenic mesenchyme 439 during the cartilage development [71], this SNP may contribute to OA through 440 disrupting the enhancer of ALDH1A2 and inappropriately activating a cell 441 differentiation pathway. In addition, we identified several aberrantly methylated 442 enhancers that may be associated with OA. One example is cg09221159 within the 443 enhancer for PTEN gene which is hypo-methylated in damaged cartilage [19] . It is 444 involved in the positive regulation of the apoptotic signaling pathway and has been 445 proposed that chondrocyte apoptosis contributes to the failure in appropriately 446 maintaining the cartilage. Thus, our analyses show that the chromatin accessibility map 447 can provide an additional layer of evidence for determining which loci, especially those 448 in the non-coding regions, are associated with OA, which may have been ignored in 449 previous studies. 450
In general, our differential enhancer analysis shows MSC, chondrocyte and 451 osteoblast-specific enhancers are dysregulated in the damaged tissues. In the integrative analysis of ATAC-seq and RNA-seq, many dysregulated 464 genes related to lineage differentiation of MSC pathways were observed. For example, 465 we found that BMPR1B (bone morphogenetic protein receptor type 1B) is upregulated 466 and both its promoter and enhancer are more accessible in the damaged tissue. Its 467 activation is consistent with the ossification pathway activation, since it encodes a 468 transmembrane serine kinase that binds to BMP ligands that positively regulate 469 endochondral ossification and abnormal chondrogenesis [74, 75] . Consistently, an 470 osteoblast marker gene MSX2 (Msh Homeobox 2) involved in promoting osteoblast 471 differentiation [76, 77] , is upregulated and both its promoter and enhancer are more 472 accessible in the damaged tissue, suggesting the osteoblast differentiation may be 473 20 activated in OA. Furthermore, we found ROR2 (receptor tyrosine kinase like orphan 474 receptor 2) is down-regulated and its enhancers are less accessible in the damaged 475 samples. Since it is required for cartilage development [78, 79] , it suggests that the 476 normal chondrocyte development and cartilage formation may be compromised in OA. 477
Consistently, we have also determined FGFR2 and STAT1, which are known to inhibit 478 chondrocyte proliferation [80] , are upregulated. In summary, our ATAC-seq data and 479 integrative analyses support the OA model of abnormal MSC differentiation and 480 endochondral ossification over other models, such as inflammatory mediums from the 481 synovium. 482
The pathogenesis for OA is not yet fully understood, despite multiple genes and 483 pathways that have been characterized to be dysregulated [13, 15, 42, 81, 82] . In this 484 study, by integrating clinically relevant epigenomic data with genetic and 485 transcriptomic data, we provide multiple lines of evidence supporting a number OA 486 candidate genes and pathways that may be crucial to OA pathogenesis, which could 487 potentially be used for clinical diagnostic or as therapeutic targets. 488 489
Conclusions 490
We present in this work an application of ATAC-seq in OA in a clinical relevant setting. 491
The chromatin accessibility map in cartilage will be a resource for future GWAS and 492 DNA methylation studies in OA and other musculoskeletal diseases. We identified 493 altered promoters and enhancers of genes that might be involved in the pathogenesis of 494 OA. Our analyses suggest aberrant enhancer usage associated with MSC differentiation 495 and chondrogenesis in OA. Understanding these molecular basis of OA is necessary for 496 future therapeutic intervention. active discussions, technical assistance and support. We thank GeNAS for the 546 sequencing service. 547 
